Crescent Biopharma AI Stock Analysis
Want to see CBIO full AI Analyst Report?
Crescent Biopharma (CBIO) AI Stock Analysis
Crescent Biopharma
(NASDAQ:CBIO)
The score is held back primarily by substantial ongoing losses and significant cash burn despite improving revenue and very high gross margins. Technically, the stock shows neutral momentum but remains below key longer-term moving averages. Valuation support is limited by negative earnings, while recent positive pipeline milestones modestly offset the risk profile.
Crescent Biopharma (CBIO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $525.59M
- Dividend Yield
- ―
- Average Volume (3M)
- 348.19K
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- 1.54
- Revenue Growth
- ―
- EPS Growth
- 67.56%
- Country
- US
- Employees
- 44
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Crescent Biopharma Business Overview & Revenue Model
Company Description
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 an...
Crescent Biopharma Earnings Call Summary
The earnings call revealed challenges with the Phase III trial not meeting its primary endpoint, leading to financial and strategic reassessments. However, there is a commitment to further analyze the rich data collected and ongoing trials continue to explore the potential of uproleselan in AML treatment.
Q1-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Q1 2024 earnings call for GlycoMimetics, the management provided updates on the Phase III study of their lead drug candidate, uproleselan, which unfortunately did not achieve a statistically significant improvement in overall survival for patients with relapsed/refractory acute myeloid leukemia (AML). The trial involved 388 patients across 70 sites in 9 countries, with a median overall survival of 13 months for the uproleselan arm and 12.3 months for the placebo arm. Despite not meeting its primary endpoint, the study's unexpected control group survival rate of over one year is considered unprecedented in this setting. The company plans to conduct a comprehensive analysis of the data in collaboration with medical, statistical, and regulatory experts and intends to present findings at a future medical meeting. Additionally, GlycoMimetics highlighted ongoing studies, including a National Cancer Institute-sponsored Phase II/III trial, and mentioned efforts to manage cash burn and revise budget plans as they proceed with further analyses and discussions with the FDA.
Crescent Biopharma Financial Statement Overview
Summary
Revenue is growing (+26.2% TTM) with exceptionally high gross margin (~99.6%) and very low leverage (debt-to-equity ~0.009), but results are dominated by large operating and net losses (net margin about -1,174%) and heavy cash burn (TTM FCF -$162.4M), keeping overall financial quality constrained despite solid capitalization.
Income Statement
24NegativeBalance Sheet
72PositiveCash Flow
29Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.00M | 10.84M | 0 | 10.00K | 75.00K | 1.16M |
| Gross Profit | 14.93M | 10.84M | 0 | 10.00K | 75.00K | 1.16M |
| EBITDA | -178.17M | -149.67M | -44.17M | -39.12M | -47.20M | -63.18M |
| Net Income | -176.09M | -153.94M | -48.52M | -36.90M | -46.69M | -63.43M |
Balance Sheet | ||||||
| Total Assets | 299.50M | 240.29M | 35.62M | 45.32M | 51.81M | 94.35M |
| Cash, Cash Equivalents and Short-Term Investments | 289.36M | 213.19M | 34.77M | 41.79M | 47.87M | 90.25M |
| Total Debt | 2.46M | 1.64M | 37.48M | 808.40K | 918.55K | 1.92M |
| Total Liabilities | 25.22M | 37.28M | 51.10M | 6.90M | 8.88M | 12.74M |
| Stockholders Equity | 274.28M | 203.01M | -15.48M | 38.41M | 42.93M | 81.60M |
Cash Flow | ||||||
| Free Cash Flow | -162.43M | -144.45M | -31.11M | -34.90M | -46.54M | -57.50M |
| Operating Cash Flow | -82.08M | -71.53M | -31.10M | -34.88M | -46.46M | -57.49M |
| Investing Cash Flow | -78.58M | -72.92M | 20.03K | -21.39K | -84.19K | -14.94K |
| Financing Cash Flow | 316.86M | 322.98M | 5,398 | 28.82M | 4.16M | 10.72M |
Crescent Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBIO, the sentiment is Neutral. The current price of 14.15 is above the 20-day moving average (MA) of 13.44, below the 50-day MA of 14.80, and below the 200-day MA of 15.95, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 52.34 is Neutral, neither overbought nor oversold. The STOCH value of 67.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CBIO.
Crescent Biopharma Risk Analysis
Crescent Biopharma disclosed 69 risk factors in its most recent earnings report. Crescent Biopharma reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksCrescent Biopharma Peers Comparison
Overall Rating
CGEN66Neutral
OBIO60Neutral
CBIO50Neutral
GUTS45Neutral
FATE42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | $198.93M | 5.40 | 39.30% | ― | 999.97% | ― | |
| 60Neutral | $570.61M | -8.15 | -140.18% | ― | 1007.38% | 50.23% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $550.37M | -2.00 | -85.44% | ― | ― | 67.56% | |
| 45Neutral | $11.99M | -0.16 | -1860.27% | ― | -100.00% | 79.01% | |
| 42Neutral | $155.61M | -1.24 | -73.92% | ― | -33.45% | 21.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CBIO | Crescent Biopharma, Inc. | 14.15 | 1.08 | 8.26% | |
| CGEN | Compugen | 2.10 | 0.51 | 32.08% | |
| FATE | Fate Therapeutics Inc | 1.28 | 0.31 | 31.55% | |
| OBIO | Orchestra Biomed Holdings, Inc. | 7.25 | 3.12 | 75.54% | |
| GUTS | Fractyl Health, Inc. | 0.90 | -16.26 | -94.74% | |
| ACTU | Actuate Therapeutics, Inc. | 0.28 | -5.63 | -95.19% |
Crescent Biopharma Corporate Events
Crescent Biopharma advances oncology pipeline and ADC programs
PositiveOn October 15, 2026, Crescent Biopharma reported progress across its oncology pipeline, highlighting completion of dose escalation and broad enrollment in the global Phase 1/2 ASCEND trial of CR-001 monotherapy, with initial safety, pharmacokinetic a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
